• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Zealand Pharma

    < Previous 1 2 Next >
    Zealand Pharma Announces Financial Results for the First Nine Months of 2024
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide
    From Zealand Pharma
    Via GlobeNewswire
    Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma Announces Financial Results for the First Half of 2024
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma Announces Financial Results for the First Quarter of 2024
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma Announces Financial Results for the Full Year 2023
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma major shareholder announcement: J O Hambro Capital Management
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma major shareholder announcement: J O Hambro Capital Management
    From Zealand Pharma
    Via GlobeNewswire
    Zealand Pharma completes registration of capital increase
    From Zealand Pharma
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.